PCL102H1 Lecture Notes - Lecture 26: Drug Discovery, Personalized Medicine, Pharmaceutical Industry

• School: UTSG
• Department: Pharmacology and Toxicology
• Course: PCL102H1
• Professor: Rebecca Laposa

Document Summary

More than half of all melanomas involve the same mutation. From a drug discovery point of view, where the tumor starts is irrelvevant, the genes and proteins matter. Theres lots of mutations in cancer, only a few are mechanistic that fuels cancers growth. In cancer research, phase 1 clinical trials are done on cancer patients. It (cid:373)atters if (cid:455)ou ha(cid:448)e the target or if (cid:455)ou do(cid:374)"t. You are only given the drug if you have the b-raf gene, everyone in the rial had the mutant b-raf protein to be in the trial. Si(cid:374)(cid:272)e it (cid:449)as(cid:374)"t a(cid:271)sor(cid:271)ed (cid:449)ell, they were going to modify it so it will be absorbed. Its hard to determine a drugs pharmacokinetics, we only know once we run the experiments. Patie(cid:374)ts (cid:449)ere eager to tr(cid:455) e(cid:454)peri(cid:373)e(cid:374)tal therapies (cid:449)he(cid:374) there is(cid:374)"t (cid:373)u(cid:272)h a(cid:448)aila(cid:271)le o(cid:374) the (cid:373)arket. Most of these drugs fail (cid:271)e(cid:272)ause the(cid:455) are (cid:374)ot (cid:373)agi(cid:272) (cid:271)ullets, the drugs are(cid:374)"t spe(cid:272)ifi(cid:272).